Dr. John Cush RheumNow
4 years 9 months ago
Medication Preferences in Patients with Psoriatic Arthritis
https://t.co/t88Kgn28F7 https://t.co/kVVd4GXd99
Dr. John Cush RheumNow
4 years 9 months ago
Guselkemab vs. Ustekinumab in PsA
https://t.co/YJ8M3byZg6 https://t.co/wxSpkvnb84
Since the start of the pandemic, hydroxychloroquine (HCQ) was forced into the limelight for the prevention/treatment of COVID-19. When it was found to be ineffective for COVID-19 and might cause potential harm, the drug came under closer scrutiny for its safety profile.
Dr. John Cush RheumNow
4 years 9 months ago
Air pollution may induce #RA flares. A Verona, Italy study of 888 pts correlated pollutants to abnormal CRP levels - Pts exposed to greater air pollutant leveles had higher risk of CRP levels ≥5 mg/l; air pollutants were higher in 60d prior to RA flares https://t.co/2ICHdxbqGS https://t.co/QGq6mQals7
Dr. John Cush RheumNow
4 years 9 months ago
Pregnancy Outcomes in PsA, SpA, RA: Dr. Rachel Tate ( @uptoTate) reviews abstracts #0369, #1722 and #1730 presented at the ACR21 annual meeting.
https://t.co/kUQReWtEdO https://t.co/MZ9Fe1Ms3N
Dr. John Cush RheumNow
4 years 9 months ago
Patient Reported Outcomes in axSpA: Dr. Swetha Alexander ( @swethaann23) reviews abstracts #0359, #0357 and #0366 presented at the ACR21 annual meeting.
https://t.co/jLJbNgZ7Vd https://t.co/yljOgrSniH
Dr. John Cush RheumNow
4 years 10 months ago
Hospitalization Trends in Patients with Psoriatic Arthritis: Dr. Olga Petryna discusses abstract #1783 presented at the ACR21 annual meeting. https://t.co/7xSb7l2Rfw
Proponents of treat to target in systemic lupus erythematosus (SLE) have all agreed that "remission" should be the goal, but defining remission may be tricky in SLE. A SLE Definitions Of Remission (DORIS)Task Force was convened in 2015 and first published their work in 2016.
Dr. John Cush RheumNow
4 years 10 months ago
444 Bio-IR or csDMARD-IR #PsA pts were Rx w/ anti-IL-23, risankizumab 150 mg Sc vs PBO at Wks 0, 4, 16, @wk 24 RIZ had significantly better ACR20 resp (51% vs 26%, p<0.001). No differences in SAE (4 vs 5.5%) or SIE (0.9% vs 2.3%). https://t.co/os2AMgG4kc
Giant cell arteritis is associated with significant treatment related morbidity due to the dependence on glucocorticoids as a treatment option. After sixty years of therapeutic stagnation, these are exciting times in the management of GCA. At this year's ACR Convergence meeting, encouraging data will be presented on options for GCA.
